1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
Helena A. Yu, Helen Ambrose, Christina S. Baik, B.C. Cho, Emiliano Cocco, Sarah B. Goldberg, Jonathan W. Goldman, Silvija Kraljevic, Adrianus J. de Langen, Isamu Okamoto, Zofia Piotrowska, Michael Pluta, S. Powar, N. Reguart Aransay, Jonathan W. Riess, Xiuning Le
Topics & Concepts
MedicineOsimertinibOncologyLung cancerInterim analysisInternal medicinenon-small cell lung cancer (NSCLC)BiomarkerCancerAdenocarcinomaClinical trialA549 cellBiochemistryROS1ChemistryLung Cancer Treatments and MutationsLung Cancer Research StudiesColorectal Cancer Treatments and Studies